๐ฐ Ctla 4 News
Page 2 - Ctla 4 News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Ctla 4. Real-time updates on events, politics, business and more.
September 28, 2023
Specialists discuss adverse reactions to immunotherapy and explore the importance of CTLA-4 inhibitors in mNSCLC treatment.
September 14, 2023
Researchers designed and evaluated a multi-epitope vaccine targeting the main outer membrane protein of Chlamydia pneumoniae using immunoinformatics.
August 28, 2023
An overview of data presented at ESMO GI 2023 on combined botensilimab and balstilimab therapy in heavily pretreated patients with microsatellite stable metastatic colorectal cancer.
August 22, 2023
Certain immune cell types are associated with immune checkpoint inhibitor (ICI) response in patients with nonโsmall cell lung cancer (NSCLC).
August 18, 2023
A research team co-led by UCLA investigators has shown that an immunotherapy drug combination can be an effective second-line therapy for patients with an aggressive and deadly type of melanoma that is resistant to the widely used immunotherapy drugs known as PD-1 inhibitors.
August 12, 2023
Glioblastoma, the most common and deadly form of brain cancer, grows rapidly to invade and destroy healthy brain tissue. The tumor sends out cancerous tendrils into the brain that make surgical tumor removal extremely difficult or impossible.
July 27, 2023
In a promising form of immunotherapy known as CAR T-cell (chimeric antigen receptor) therapy, the patient's T cells are engineered to better recognize and attack antigens on the surface of cancer cells.
July 26, 2023
Researchers evaluate the impact of tumor-derived GDF-15 on responses to anti-PD-1 immunotherapy.
June 6, 2023
Researchers describe the Treg-cell-inducing activity of lipid extracts from the feces of specific-pathogen-free mice.
April 18, 2023
Results from the S1609 DART clinical trial, which tested an immunotherapy combination of ipilimumab plus nivolumab in 53 cohorts of patients with rare cancers, are being reported for five cohorts of patients who had rare gynecologic cancers.